PRESS RELEASE: Shionogi-ViiV Healthcare LLC -2-
22nd Jul 2010 13:45
GlaxoSmithKline disclosure notice: Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK including those made in this announcement, are subject to risks and uncertainties th
Read morePRESS RELEASE: Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference
22nd Jul 2010 13:45
Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 Study Antiviral activity shown by S/GSK1349572 in treatment-experienced subjects resistant to raltegravir from VIKING Study VIENNA, July 22 /PRNewswire/ -- Shionogi-ViiV Healthcare LLC today reported data from
Read moreShionogi-ViiV Healthcare: 572 HIV Drug Shows Potent Antiviral Activity
22nd Jul 2010 13:30
LONDON (Dow Jones)-- Shionogi-ViiV Healthcare LLC, announced Thursday data from two Phase IIb studies showing that its once-daily, unboosted investigational HIV integrase inhibitor, S/GSK1349572 or '572, exhibited potent antiviral activity in treatment-naive HIV subjects as well as in treatment-expe
Read moreThursday tips round-up: GSK, Hochschild Mining, De La Rue
22nd Jul 2010 06:14
Announcing yesterday's second-quarter numbers, GlaxoSmithKline said it might start a shares buyback programme, which could help the share price. GSK has ruled itself out of any bidding war for the Durex maker SSL, which yesterday recommended a bid from Reckitt Benckiser. The stars are starting to al
Read morePharmaceutical Groups To Give Generic Drug Makers Access To HIV Medicines - FT
22nd Jul 2010 02:42
DOW JONES NEWSWIRES Three of the world's largest pharmaceutical groups will offer generic drugs manufacturers royalty-free rights to all their existing and experimental HIV medicines to sell at low cost in developing countries, the Financial Times reported on its website Wednesday, citing Viiv
Read moreGlaxoSmithKline Suspends Thiazolidinedione Trial At FDA Request
21st Jul 2010 18:34
LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK.LN) said Wednesday in response to a Food and Drug Administration, or the FDA, announcement on TIDE trial, the company confirmed it will suspend enrollment of new patients in the Thiazolidinedione Intervention with Vitamin D Evaluation (TIDE) clinical tria
Read moreFDA Puts Ongoing Glaxosmithkline Avandia Study On Partial Hold
21st Jul 2010 17:52
By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--The Food and Drug Administration said Wednesday it's placed a partial hold on an ongoing clinical study involving GlaxoSmithKline PLC's (GSK) diabetes drug Avandia. The study, known as TIDE, is designed to compare
Read moreLondon close: Good gains for FTSE 100
21st Jul 2010 17:04
Footsie's advance was pared slightly at the close of trading but shares still finished with strong gains. Mining stocks led the advance as copper inventories continue to contract, with Kazakhmys, Antofagasta, Vedanta and Xstrata at the head of the pack. Sticking with the resource sector, mining a
Read moreUK MARKET TALK ROUNDUP: SHARES GAINING
21st Jul 2010 14:17
Stocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 1317 GMT [Dow Jones] GlaxoSmithKline's (GSK.LN) 2Q update is solid, with EPS slightly ahead of expectations and consensus,
Read moreMARKET TALK: GlaxoSmithKline 2Q Update Solid - Evolution
21st Jul 2010 14:17
1317 GMT [Dow Jones] GlaxoSmithKline's (GSK.LN) 2Q update is solid, with EPS slightly ahead of expectations and consensus, and sales in-line, says Evolution Securities. Evolution notes beating of consensus by a small margin was mainly driven by a lower tax rate. Noteworthy contributors to profit gro
Read moreLondon afternoon: Three-digit gain for Footsie
21st Jul 2010 14:10
Footsie's gain burst through the triple digit barrier over the lunchtime session, helped by expectations of a solid start by Wall Street. Mining stocks lead the advance as copper inventories continue to contract, with Kazakhmys, Antofagasta, Vedanta and Xstrata at the head of the pack. Sticking
Read moreBEFORE THE BELL: US Stock Futures Higher Buoyed By Apple Results
21st Jul 2010 14:01
By Polya Lesova U.S. stock futures gained on Wednesday, buoyed by strong results from blue-chip firms including Morgan Stanley and Apple, as investors braced for testimony by Federal Reserve Chairman Ben Bernanke. Futures on the Dow Jones Industrial Average rose 43 points to 10221. Nasdaq 1
Read moreUPDATE: Glaxo Quarterly Results Hit By Legal Charge, Generics
21st Jul 2010 14:00
(Adds detail, CEO and analyst comment.) By Sten Stovall Of DOW JONES NEWSWIRES LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK, GSK.LN) Wednesday missed earnings forecasts for the second quarter as continued strong sales of new products and its pandemic flu vaccine and further expansion in
Read moreBEFORE THE BELL: US Stock Futures Up Before Bernanke Testimony
21st Jul 2010 13:05
By Polya Lesova U.S. stock futures gained on Wednesday, buoyed by Apple's stronger-than-expected results, as investors braced for testimony by Federal Reserve Chairman Ben Bernanke and another barrage of earnings reports. Futures on the Dow Jones Industrial Average rose 15 points to 10193.
Read moreUK MARKET TALK ROUNDUP: SHARES GAINING
21st Jul 2010 12:29
Stocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 1129 GMT [Dow Jones] Top line progression in GlaxoSmithKline's (GSK.LN) 1H results is pleasing, as is the significant cash
Read more